Visfatin Levels May be an Early Marker of Atherosclerosis in Patients with Acromegaly

Abstract

The purpose of the study was to compare serum visfatin levels between patients with acromegaly and healthy controls and to evaluate the relationships between visfatin levels and epicardial fat thickness (EFT), carotid intima media thickness (cIMT), and ankle brachial index (ABI). We conducted a cross-sectional case-control study of 54 patients with acromegaly (37 females and 17 males) and 34 healthy controls (22 females and 12 males). Serum visfatin was measured by ELISA. Acromegalic and control participants and those with active or controlled acromegaly were compared with respect to their serum visfatin, clinical and metabolic parameters, EFT, cIMT, and ABI. Linear correlation was used to identify associations between these parameters and visfatin in all participants. Serum visfatin and glycated hemoglobin (HbA1c) were higher in the acromegaly group than in the control group (p<0.001 and p=0.007, respectively). There was no difference in visfatin between the active and controlled acromegaly groups, but HbA1c was higher in the active than the controlled acromegaly group (p<0.04). EFT, cIMT, and ABI were similar between the acromegaly and control groups and between the active and controlled acromegaly groups. Serum visfatin positively correlated with HbA1c, growth hormone (GH), and insulin-like growth factor-1 (IGF-1)/upper limit of normal ratio (r=0.245, p=0.024; r=0.259, p=0.017; and r=0.282, p=0.009, respectively). This study has revealed that a high visfatin level is associated with glycemic dysregulation and higher levels of GH and IGF-1 in acromegalic patients.

Key words

visfatin - acromegaly - diabetes mellitus - epicardial fat thickness - carotid intima media thickness

• References

• 1 Katznelson L, Laws Jr. ER, Melmed S. et al. Endocrine Society. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 3933-3951
• 2 Melmed S, Casanueva FF, Klibanski A. et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013; 16: 294-302
• 3 Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009; 30: 152-177
• 4 Frara S, Maffezzoni F, Mazziotti G. et al. Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab 2016; 27: 470-483
• 5 Dogansen SC, Yalin GY, Tanrikulu S. et al. Impact of glucose metabolism disorders on IGF-1 levels in patients with acromegaly. Horm Metab Res 2018; 50: 408-413
• 6 Mercado M, Ramírez-Rentería C. Metabolic complications of acromegaly. Front Horm Res 2018; 49: 20-28
• 7 Ritvonen E, Löyttyniemi E, Jaatinen P. et al. Mortality in acromegaly: A 20-year follow-up study. Endocr Relat Cancer 2016; 23: 469-480
• 8 Olarescu NC, Bollerslev J. The impact of adipose tissue on IR in acromegaly. Trends Endocrinol Metab 2016; 27: 226-237
• 9 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556
• 10 Fukuhara A, Matsuda M, Nishizawa M. et al. Visfatin: a protein secreted by visceral fat that Mimics the effects of insulin. Science 2005; 307: 426-430
• 11 Uzun G, Ozden S. Visfatin and its effects. Journal of Turkish Clinical Biochemistry 2013; 11: 119-130
• 12 Sucunza N, Barahona MJ, Resmini E. et al. A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. J Clin Endocrinol Metab 2009; 94: 3889-3896
• 13 Olarescu NC, Ueland T, Lekva T. et al. Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly. J Clin Endocrinol Metab 2012; 97: 1355-1362
• 14 Ciresi A, Amato MC, Pizzolanti G. et al. Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations. Growth Horm IGF Res 2015; 25: 240-246
• 15 Cansu GB, Yılmaz N, Yanıkoğlu A. et al. Assessment of diastolic dysfunction, arterial stiffness, and carotid intima-media thickness in patients with acromegaly. Endocr Pract 2017; 23: 536-545
• 16 Ozkan C, Altinova AE, Cerit ET. et al. Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly. Pituitary 2015; 18: 621-629
• 17 World Health Organization. Physical Status: The use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995; 854: 1-452
• 18 American Diabetes Association. Standarts of medical care in in diabetes. Classification and diagnosis of diabetes mellitus. Diabetes Care 2016; 39: 13-23
• 19 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: IR and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
• 20 Iacobellis G, Ribaudo MC, Assael F. et al. Echocardio-graphic epicardial adipose tissue is related to anthropometricand clinical parameters of metabolic syndrome: A new indicatorof cardiovascular risk. J Clin Endocrinol Metab 2003; 88: 5163-5168
• 21 Fowkes FG, Murray GD, Butcher I. et al. Ankle brachial index combined with Framingham Risk Score to predict cardio-vascular events and mortality: A meta-analysis. JAMA 2008; 300: 197-208
• 22 Giustina A, Chanson P, Bronstein MD. et al. Acromegaly Consensus Group A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010; 95: 3141-3148
• 23 Goodman HM. Multiple effects of growth hormone on lipolysis. Endocrinology 1968; 83: 300-308
• 24 Freda PU, Shen W, Heymsfield SB. et al. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth fact or I excess due to acromegaly. J Clin Endocrinol Metab 2008; 93: 2334-2343
• 25 Ciresi A, Amato MC, Pivonello R. et al. The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 2013; 98: 51-59
• 26 Moschen AR, Kaser A, Enrich B. et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758
• 27 Dahl TB, Yndestad A, Skjelland M. et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization. Circulation 2007; 115: 972-980
• 28 Chen MP, Chung FM, Chang DM. et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299
• 29 Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M. et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55: 2871-2875
• 30 Li L, Yang G, Li Q. et al. Changes and relations ofcirculating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006; 114: 544-548
• 31 Gunduz FO, Yildirmak ST, Temizel M. et al. Serum visfatin and fetuin-A levels and glycemic control in patients with obese type 2 diabetes mellitus. Diabetes Metab J 2011; 35: 523-538
• 32 Taskesen D, Kirel B, Us T. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol 2012; 4: 76-81
• 33 Olszanecka-Glinianowicz M, Owczarek A, Bożentowicz-Wikarek M. et al. Relationship between circulating visfatin/NAMPT, nutritional status and IR in an elderly population - results from the PolSenior substudy. Metabolism 2014; 63: 1409-1418
• 34 Dogru T, Sonmez A, Tasci I. et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007; 76: 24-29
• 35 Turgut S, Topsakal S, Ata MT. et al. Leptin receptor gene polymorphism may affect subclinical atherosclerosis in patients with acromegaly. Avicenna J Med Biotech 2016; 8: 145-150
• 36 Topsakal S, Akin F, Turgut S. et al. Relationship of apelin, procalcitonin, and fetuin-A concentrations with carotid intima-media thickness in acromegaly. Ann Clin Biochem 2015; 52: 456-461